Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
174
resultados
Última actualización
10/09/2026 [06:48:00]
Resultados 50 a 75 de 174
Resumen de: CN122685654A
本发明属于生物医药的技术领域，公开了一种核酸药物选择性递送的膦酯化可电离脂质及其制备方法与应用。所述膦酯化可电离脂质其结构通式为式I，式I中Cn为含有膦酯的结构，Nn为含氮的环状结构或含氮的胺基基团，B为O或NH；Ln作为连接键。本发明还公开了膦酯化可电离脂质的制备方法。本发明的膦酯化可电离脂质用于制备膦酯化可电离脂质纳米颗粒，作为核酸药物选择性递送至心、肺脏、脾脏、肝脏和/或肌肉递送载体。本发明的可电离脂质协同整合了膜稳定性与内涵体逃逸功能，有效规避传统靶向修饰中存在的蛋白冠屏蔽效应，能够将核酸药物高效、安全地递送至肝外器官，特别是肺和脾。式I：。
Resumen de: CN122681822A
本发明涉及生物医药技术领域，且公开了一种巨噬细胞膜仿生纳米粒靶向SPP1抗肾纤维化药物系统，该系统包含PLGA纳米粒内核、能够结合并中和SPP1蛋白活性的抗体以及具有炎症趋化和病灶归巢能力的巨噬细胞膜包裹层，抗体负载于PLGA纳米粒内核表面，巨噬细胞膜包裹层包覆于负载抗体的PLGA纳米粒外表面形成核‑壳结构。制备方法包括滴加法制备PLGA纳米粒、抗体负载、低渗裂解提取巨噬细胞膜、超声和挤出完成膜包裹。该系统利用巨噬细胞膜天然携带的炎症趋化受体实现肾纤维化病灶主动靶向归巢，在肾纤维化模型中能够降低纤维化面积，促进E‑cadherin恢复，延长体内循环时间，提高病灶富集浓度。
Resumen de: CN122682090A
本发明公开了一种用于椎间盘退变修复的聚多巴胺修饰ZnO/BaTiO3异质结复合材料及其制备方法，属于生物医用材料技术领域。该材料以四方相钛酸钡为核心、表面原位生长氧化锌构建II型异质结，并包覆聚多巴胺功能层。制备时，先水热法制备钛酸钡，再经溶剂蒸发与高温煅烧引入氧化锌，最后在多巴胺溶液中自聚包覆。本发明利用超声驱动异质结产生声电耦合效应，II型异质结促进载流子分离以提升压电催化活性，PDA涂层清除活性氧、缓解炎症。体外实验证实该材料促进髓核细胞基质合成、抑制炎症，动物实验验证其延缓椎间盘退变。本发明通过“声电转化‑电荷分离‑电刺激‑环境重塑”一体化设计，为深部组织修复提供了高效无创策略。
Resumen de: CN122681819A
本发明公开一种负载二烯丙基三硫化物的长双歧杆菌来源细胞外囊泡纳米复合物，包括：长双歧杆菌来源细胞外囊泡（BL‑EVs），以及负载于BL‑EVs中的二烯丙基三硫化物（DATS）；纳米复合物是通过将BL‑EVs与DATS混合后进行共挤出及孵育处理制得的、具有单分散囊泡结构的纳米复合物实体。本发明的纳米复合物具备细胞内微环境刺激响应性，在被牙周相关细胞摄取进入胞内后，特异性响应于胞内谷胱甘肽微环境触发内部有机硫键断裂，并在胞内靶向缓释硫化氢，用以通过上调靶细胞抗氧化保护蛋白的表达与活性以产生抗氧化增效作用，并在此基础上，协同诱导巨噬细胞向抗炎修复型M2巨噬细胞重塑，同时上调牙龈成纤维细胞抗铁死亡保护蛋白的表达与活性以阻断其铁死亡进程。
Resumen de: CN122681817A
本发明公开了一种纳米材料Q‑MNPS及其制备方法和在脑缺血神经保护中的制药新用途，涉及生物医药技术领域。包括：金属‑药物配位聚合物内核；包覆所述内核的天然细胞膜外壳；其中，所述金属‑药物配位聚合物内核在活性氧环境下发生解离，释放药物分子；所述天然细胞膜外壳赋予所述纳米颗粒穿透血脑屏障的能力。本发明通过天然细胞膜外壳的生物伪装特性实现血脑屏障穿透，利用金属‑药物配位聚合物内核的活性氧响应性在缺血病灶定点释放药物，具有优异的神经保护作用，能够显著改善神经功能缺损并降低死亡率。
Resumen de: CN122681823A
本发明公开了一种透明质酸、L‑精氨酸包覆复合纳米粒子及其制备方法，涉及医药技术领域；该复合纳米粒子以β‑环糊精包载伏立诺他（SAHA）形成纳米粒子，外层包覆氧化透明质酸（OHA）和L‑精氨酸（L‑Arg）；制备过程中，先通过透析法制得纳米粒子，再依次加入OHA和L‑Arg进行避光反应，最终得到CS@OL复合纳米粒子；该粒子平均粒径为87nm，在室温下21天内保持稳定。本发明复合纳米粒子具有良好的自由基清除能力、细胞相容性、跨内皮递送能力及靶向炎症细胞的能力，能够协同递送SAHA和L‑Arg，调节ROS/NO稳态，抑制炎症反应，适用于动脉粥样硬化等氧化应激相关疾病的治疗。
Resumen de: CN122686807A
本发明涉及生物医药技术领域，具体涉及用于特异性检测tRNA来源小片段RNA 5‑GlyTCC‑L33表达水平的试剂在制备用于胎儿生长受限辅助评估产品中的应用，5‑GlyTCC‑L33模拟物在制备用于胎儿生长受限实验动物模型构建的模型诱导试剂或模型诱导组合物中的应用，以及相关试剂盒；本发明通过对正常妊娠与胎儿生长受限胎盘组织进行小RNA测序分析，发现5‑GlyTCC‑L33在胎儿生长受限胎盘组织中显著上调，通过检测离体胎盘绒毛膜组织样本中5‑GlyTCC‑L33的表达水平，并与正常妊娠对照水平或预设参考阈值比较，可生成体外检测结果或辅助判读信息可作为胎儿生长受限辅助评估的候选分子标志物。
Resumen de: US20260256146A1
0000 A cerium oxide nanoparticle is produced by adding an oxidant to a solution comprising a boron compound represented by formula (I) and a cerium (III) ion:
0000
wherein n represents an integer of 0 to 2, R represents any of an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and R′ represents any of a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, a phenyl group, and a tolyl group, and when a plurality of Rs or of R's are present, the plurality of Rs or of R's are optionally the same or different.
Resumen de: CN115484932A
Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents to alter the expression and function of target genes, such as proteins involved in lipid and cholesterol metabolism, such as PCSK9. Also provided herein are compositions and methods for treating conditions associated with coronary artery disease.
Resumen de: US20260256690A1
Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregnant mother. Fibroblast growth factor is to correct structural defects of neural tissue.
Resumen de: AU2026216842A1
The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen. ug u g
Resumen de: US20260256776A1
Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.
Resumen de: WO2025049928A1
A gene editing system comprising (a) a fusion polypeptide comprising a CRISPR nuclease and a reverse transcriptase, or a nucleic acid encoding the fusion polypeptide, and (b) an RNA molecule comprising a guide RNA and a reverse transcription donor RNA, or a nucleic acid encoding the RNA molecule. Also provided herein are methods of using the gene editing system for modifying target genes of interest.
Resumen de: US20260256707A1
Disclosed herein are aspects of a compound according to Formula IAlso disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and/or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some aspects, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.
Resumen de: WO2026183193A1
Disclosed are nanoparticles and compositions thereof for delivering active agents to the kidney. The nanoparticles include a dendrimer, a targeting ligand, and one or more active agents. From 5% to less than 90% of the dendrimer's surface groups can be modified with one or more functional groups e.g., acetyl groups. The dendrimer can be a PAMAM dendrimer or a saccharide dendrimer. The targeting ligand, such as folic acid, is conjugated to unmodified surface groups. Active agents, including small molecules (e.g., PPAR-α agonists), peptides, or nucleic acids, are encapsulated or associated with the nanoparticles. The nanoparticles have a neutral or positive zeta potential, ranging from about 0 mV to about 30 mV, and a diameter of ranging from 1 to 30 nm. Also disclosed are methods of administering the nanoparticle compositions for treating kidney diseases in a subject in need thereof.
Resumen de: WO2026181080A1
Metal nanoparticles comprising at least one metal atom and a ligand associated with at least a portion of a surface of the metal atom, and uses thereof, are provided. The ligand is made of a first moiety (denoted as X) that is capable of associating with the surface of the metal atom; and an additional moiety (denoted as Y) which is a redox-reactive moiety and/or a second moiety that is capable of associating with the surface of the metal atoms, and optionally a linking moiety that links the first moiety and the additional moiety. The metal nanoparticles are ultra-small nanoparticles. The metal nanoparticles are usable in, for example, catalyzing redox reactions and as coatings for varying surfaces, and are capable of interacting with a myriad of substances, such as liposomes and oligonucleotides, rendering these nanoparticles usable in varying applications.
Resumen de: WO2026183437A1
Provided herein are pharmaceutical compositions that include (a) a dendrimer nanoparticle, wherein the dendrimer nanoparticle comprises Dexamethasone-21-succinate, and (b) a plurality of retinal cells. Also provided herein are methods for treating a degenerative and hereditary retinopathy that include administering any one of the pharmaceutical compositions described herein to a subject in need thereof.
Resumen de: WO2026183342A1
The present technology relates generally to nanoparticles including bovine serum albumin and a first copper complex including diethyldithiocarbamate and Cu2+, and optionally including a second copper complex including diethyldithiocarbamate and 64Cu2+, and optionally including a third copper complex including diethyldithiocarbamate and 67Cu2+ for treating, imaging, and/or detecting a cancer.
Resumen de: WO2026180744A1
The invention provides a lipid composition or LNP comprising (i) one or more cationic ionizable lipids and, optionally, one or more permanent cationic lipids, (ii) one or more phospholipids, (iii) one or more amphiphilic compounds comprising a hydrophilic polymer chain having one or more hydrophobic groups, (iv) optionally cholesterol or a cholesterol ester, (v) a lipophilic agent other than cholesterol and a cholesterol ester, and (vi) one or more polynucleotide(s).
Resumen de: US20260256709A1
0000 Described herein are methods, systems and compositions for the production and use of a class of highly branched, nanostructured particles, generally referred to herein as dendritic particles (DPs), synthesized from biodegradable materials that are specifically adapted for drug release in vivo.
Resumen de: US20260256942A1
The present disclosure discloses a nanocarrier composition with adjustable structure, preparation method and use thereof. The nanocarrier composition is prepared by adding a regulator to lecithin. By adding different types of regulators, the nanocarrier composition can be converted between a liposome structure or a micelle structure. When applied to medical purposes, under the same nanocarrier composition preparation process, under the same nanocarrier composition manufacturing process, the structure of the nanocarrier composition can be changed by simply changing the type of added regulator, thereby controlling the drug release time, drug penetration and bioavailability. The nanocarrier composition can be converted into a suitable structure to facilitate drug delivery according to the requirements of different dosage forms.
Resumen de: US20260256943A1
Generally, a nanomaterial polymer encapsulation system useful in the production of nanocomposites comprising an inorganic nanoparticle encapsulated in a hydrophobic region of a polymer with the external hydrophilic region of the polymer ensuring water-solubility and affording a functional group which can be utilized for the production of nanocomposite conjugates.Specifically, particular embodiments can comprise nanocomposites including one or more inorganic nanoparticles including, metal and non-metal isotopes, a superparamagnetic iron oxide nanoparticle (“SPION”), and/or quantum dots encapsulated in a polystyrene-b-polyethylene glycol affording a functional group that can be activated to conjugate antibodies, modified antibodies, or antibody fragments for the capture of target moieties which in suspension can be nebulized into an inductively coupled plasma time-of-flight mass spectrometry instrument to identify and quantify diverse features of cellular systems.
Resumen de: WO2026178657A1
Described herein are pH-responsive synthetic peptide shuttle agent having increased cargo transduction activity at acidic pH than at neutral pH. The pH-responsive synthetic peptide shuttle agent generally comprises an amphipathic alpha-helical motif when in acidic pH, the amphipathic alpha-helical motif having solvent-exposed surface comprising a discrete hydrophilic cationic face and a discrete hydrophobic face. The pH-responsive synthetic peptide shuttle agent described herein may be further conjugated to a cargo for intracellular delivery, and/or a targeting ligand for tissue-specific delivery. Also described herein are lipid nanoparticles (LNPs) incorporating synthetic peptide shuttle agents or pH- responsive synthetic peptide shuttle agents for improved payload delivery to the cytosol.
Resumen de: WO2026179355A1
The present application provides a branched cationic lipid containing an ester bond, the structure of which is represented by formula (1), wherein the definition of each symbol is consistent with that described herein. The branched cationic lipid containing an ester bond has a plurality of hydrophobic hydrocarbon tail chains. The cross-sectional area of the hydrophobic end increases, forming a conical geometric configuration, which is conducive to promoting membrane fusion and content release; moreover, a charged head group can interact with oppositely charged molecules on the cell membrane, thereby enabling the multi-tailed lipid to pass through the cell membrane more easily and exert its endosome-disrupting effect inside the cell, and thus improving drug release efficiency. The branched cationic lipid containing an ester bond of the present application comprises one or more biodegradable groups between a branching center and the hydrophobic tails. The presence of the degradable groups enables a lipid nanoparticle (LNP) prepared from the branched cationic lipid to be degraded timely within endosomes, such that the endosomal escape of drug molecules (such as nucleic acids) is promoted, thereby solving the problem that drugs delivered into the cell fail to exert their effects.
Nº publicación: US20260258413A1 03/09/2026
Solicitante:
CREATE MEDICINES INC [US]
CREATE Medicines, Inc.
Resumen de: US20260258413A1
Compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for stable and durable expression are described and can be suitably used for immunotherapy in cancer or infection.
BOPI
Sede Electrónica
